Aspirin resistance and its implications in clinical practice

MedGenMed Medscape General Medicine

Volumn 7, Issue 3, 2005, Pages

  Eikelboom, John ^a   Feldman, Mark ^b   Mehta, Shamir R ^c   Michelson, Alan D ^d   Oates, John A ^e   Topol, Eric ^f   Riesman, Miriam ^g   Lande, Stephen D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g Interactive Forums Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PROSTAGLANDIN SYNTHASE; THROMBOXANE; 11 OXOTHROMBOXANE B2; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; THROMBOXANE A2;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DOSE RESPONSE; DRUG MECHANISM; DRUG SUBSTITUTION; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MORTALITY; PATIENT COMPLIANCE; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING; CONFERENCE PAPER; DRUG EFFECT; DRUG RESISTANCE; THROMBOCYTE; ASPIRIN RESISTANCE; ASTHMA; CYTOMETRY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; INTERNATIONAL COOPERATION; INTESTINE ULCER; MEDICAL EXPERT; PRACTICE GUIDELINE; PRESCRIPTION; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; STOMACH ULCER; THROMBOCYTE AGGREGATION; TURBIDIMETRY;

ASPIRIN; BLOOD PLATELETS; DRUG RESISTANCE; HUMANS;

EID: 25144476201     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
2. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
3. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S-63S.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
5. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399-406.
6. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.
7. Serebruany VL, Malinin AI, Sane DC. Risk of bleeding complications with antiplatelet agents: a meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75:40-7.
8. Eikelboom JW, Hirsh J, Weitz JL, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
9. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965.
10. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122-1126.
11. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to a low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78:1003-1007.
12. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin nonresponder: a pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397-403.
13. Michelson AD, Barnard MR, Krueger LA, et al. Flow cytometry. In: Michelson AD, ed. Platelets. San Diego, Calif: Academic Press; 2002:297-315.
14. Hennekens CH, Schror K, Weisman S, GitzGeral GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation 2004;110:1706-1708.
15. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:e489-e493.
16. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250:63-66.
17. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413-16.
18. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117:17-25.
19. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.